Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE versus NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE versus NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
DROSPIRENONE vs NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Spironolactone analog that antagonizes aldosterone at the mineralocorticoid receptor, leading to increased sodium and water excretion and potassium retention. Also has antiandrogenic activity by blocking androgen receptors and decreasing ovarian androgen production via inhibition of gonadotropin release.
Combination of norethindrone acetate (progestin) and ethinyl estradiol (estrogen) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering endometrial lining to reduce implantation. Ethinyl estradiol (in 7-day extended regimen) maintains hormone levels. Ferrous fumarate provides iron supplementation.
3 mg orally once daily.
One tablet (containing norethindrone acetate 1 mg, ethinyl estradiol 20 mcg, and ferrous fumarate 75 mg) orally once daily for 28-day cycle (21 active pills, 7 placebo with ferrous fumarate).
None Documented
None Documented
Clinical Note
moderateDrospirenone + Benzydamine
"Drospirenone may increase the hyperkalemic activities of Benzydamine."
Clinical Note
moderateDrospirenone + Droxicam
"Drospirenone may increase the hyperkalemic activities of Droxicam."
Clinical Note
moderateDrospirenone + Loxoprofen
"Drospirenone may increase the hyperkalemic activities of Loxoprofen."
Clinical Note
moderateDrospirenone + Clonixin
"Drospirenone may increase the hyperkalemic activities of Clonixin."
Terminal elimination half-life: ~30-35 hours (range 25-40 h); significant clinical accumulation occurs after repeated dosing, requiring 10-14 days to reach steady state.
Norethindrone: Terminal half-life approximately 8–11 hours. Ethinyl estradiol: Terminal half-life approximately 13–27 hours (mean 17 hours). Clinical context: Steady state reached after 5–7 days.
Renal: ~50% (as metabolites; <10% unchanged); Fecal: ~40-50% (as metabolites; bile-mediated); Urinary and fecal elimination account for >95% of an oral dose.
Norethindrone acetate: Urine (39% as metabolites, 1% unchanged); Feces (35% as metabolites). Ethinyl estradiol: Urine (40% as glucuronide conjugates, <1% unchanged); Feces (40% as metabolites). Ferrous fumarate: Iron absorbed and utilized; unabsorbed iron excreted in feces.
Category C
Category D/X
Progestin
Progestin